Exploratory secondary analysis of FINE-ONE (242 adults with type 1 diabetes and CKD): finerenone cut UACR by 25% vs placebo over 6 months, consistently across baseline HbA1c tertiles (P interaction 0.41) and diabetes duration; hyperkalaemia similar across HbA1c groups.
Secondary analysisn = 242
Beernink et al. Effect of Finerenone on Albuminuria in Type 1 Diabetes by Baseline HbA1c Level and Diabetes Duration: An Exploratory Analysis of the FINE-ONE Trial